Literature DB >> 12938096

Identification and characterization of genomic rearrangements of MSH2 and MLH1 in Lynch syndrome (HNPCC) by novel techniques.

Hidewaki Nakagawa1, Heather Hampel, Albert de la Chapelle.   

Abstract

It has recently been suggested that large genomic rearrangements account for 10-20% of all MSH2 mutations, and a lower proportion of all MLH1 mutations, among individuals with Lynch syndrome (hereditary non-polyposis colorectal cancer, HNPCC). These rearrangements are notoriously difficult to detect; moreover, for clinical purposes, simple tests must be devised to screen family members at risk. Here we used the multiplex ligation-dependent probe amplification (MLPA) method to screen for MSH2 and MLH1 deletions in 70 patients whose colorectal or endometrial tumors were MSI positive, yet no mutation had been found by genomic exon-by-exon sequencing of MSH2, MLH1, and MSH6. We identified five candidates with four different MSH2 deletions (exons 1-2, exons 1-6, exons 1-7 and exon 8) and one candidate with an MLH1 deletion (exons 3-6). To confirm the screening results and to characterize the breakpoints of these genomic deletions precisely, we used diploid-to-haploid conversion and inverse PCR as well as long-range PCR. In each case, we were able to pinpoint the breakpoint and design a simple diagnostic PCR. The procedures we used appear to be sensitive, specific, and simple enough for clinical use. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12938096     DOI: 10.1002/humu.9171

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  27 in total

1.  A unique MSH2 exon 8 deletion accounts for a major portion of all mismatch repair gene mutations in Lynch syndrome families of Sardinian origin.

Authors:  Iolanda Borelli; Marco A Barberis; Francesca Spina; Guido C Casalis Cavalchini; Caterina Vivanet; Luisa Balestrino; Monica Micheletti; Anna Allavena; Paola Sala; Carlo Carcassi; Barbara Pasini
Journal:  Eur J Hum Genet       Date:  2012-07-11       Impact factor: 4.246

Review 2.  Molecular basis for subdividing hereditary colon cancer?

Authors:  W M Grady
Journal:  Gut       Date:  2005-12       Impact factor: 23.059

3.  Germline MLH1 and MSH2 mutational spectrum including frequent large genomic aberrations in Hungarian hereditary non-polyposis colorectal cancer families: implications for genetic testing.

Authors:  Janos Papp; Marietta E Kovacs; Edith Olah
Journal:  World J Gastroenterol       Date:  2007-05-21       Impact factor: 5.742

4.  Conversion analysis for mutation detection in MLH1 and MSH2 in patients with colorectal cancer.

Authors:  Graham Casey; Noralane M Lindor; Nickolas Papadopoulos; Stephen N Thibodeau; John Moskow; Scott Steelman; Carolyn H Buzin; Steve S Sommer; Christine E Collins; Malinda Butz; Melyssa Aronson; Steven Gallinger; Melissa A Barker; Joanne P Young; Jeremy R Jass; John L Hopper; Anh Diep; Bharati Bapat; Michael Salem; Daniela Seminara; Robert Haile
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

5.  Germline mutations of the hMLH1 and hMSH2 mismatch repair genes in Belgian hereditary nonpolyposis colon cancer (HNPCC) patients.

Authors:  M Spaepen; B Vankeirsbilck; S Van Opstal; S Tejpar; E Van Cutsem; K Geboes; E Legius; G Matthijs
Journal:  Fam Cancer       Date:  2006       Impact factor: 2.375

6.  Accuracy of MSI testing in predicting germline mutations of MSH2 and MLH1: a case study in Bayesian meta-analysis of diagnostic tests without a gold standard.

Authors:  Sining Chen; Patrice Watson; Giovanni Parmigiani
Journal:  Biostatistics       Date:  2005-04-14       Impact factor: 5.899

7.  Some aspects of molecular diagnostics in Lynch syndrome.

Authors:  Grzegorz Kurzawski
Journal:  Hered Cancer Clin Pract       Date:  2006-12-15       Impact factor: 2.857

8.  Comprehensive molecular analysis of mismatch repair gene defects in suspected Lynch syndrome (hereditary nonpolyposis colorectal cancer) cases.

Authors:  James Mueller; Isabella Gazzoli; Prathap Bandipalliam; Judy E Garber; Sapna Syngal; Richard D Kolodner
Journal:  Cancer Res       Date:  2009-08-18       Impact factor: 12.701

9.  Some molecular and clinical aspects of genetic predisposition to malignant melanoma and tumours of various site of origin.

Authors:  Tadeusz Debniak
Journal:  Hered Cancer Clin Pract       Date:  2007-06-15       Impact factor: 2.857

10.  Dosage analysis of cancer predisposition genes by multiplex ligation-dependent probe amplification.

Authors:  D J Bunyan; D M Eccles; J Sillibourne; E Wilkins; N Simon Thomas; J Shea-Simonds; P J Duncan; C E Curtis; D O Robinson; J F Harvey; N C P Cross
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.